Purple Biotech Ltd. Sponsored ADR PPBT
1.49
0.01
0.68%
as of 25 Sep
- Market cap
- $2.4M
- P/E
- 0.0×
Follow PPBT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
| ROE |
+8 more TTM periods Free account |
(10.44%) | (123.97%) | (122.85%) | (110.67%) |
| ROA | (8.77%) | (96.63%) | (104.05%) | (100.91%) | |
| ROIC | (13.86%) | (20,189.71%) | (546.31%) | (290.25%) | |
| Return on Tangible Assets | (67.18%) | (1,179.53%) | (1,129.79%) | (497.62%) | |
| Average Days of Receivables | — | — | — | — | |
| Free Cash Flow per Share | (14.48) | (11.79) | (7.31) | (7.15) | |
| Free Cash Flow | (6.60) | (5.66) | (6.80) | (7.76) | |
| Capital Expenditures | 0.01 | 0.00 | — | (0.01) | |
| Other line items | |||||
| Cash ROIC | (15.26%) | (29.41%) | (42.26%) | (42.35%) | |
| Accounts Payable Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Average Days of Payables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Selling, General and Administrative Expense of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Share Based Compensation of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF/Net income | 2.03 | 0.21 | 0.26 | 0.32 | |
| Depreciation/Fixed assets | 1.56 | 1.64 | 1.91 | 2.14 | |
| Capex/Depreciation | 0.04 | (0.01) | 0.00 | (0.02) | |
| Revenue per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF per Share | (14.50) | (11.78) | (7.31) | (7.14) | |
| Capex per Share | 0.02 | (0.01) | 0.00 | (0.01) | |
| Capex to Sales | 0.00 | 0.00 | — | 0.00 | |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates